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This paper describes the treatment of a severe case of acute mountain sickness with a portable
hyperbaric chamber. A 37-year old climber was treated for acute high altitude pulmonary oedema,
which developed on the North Col of Mount Everest, at an altitude of 7,060 m. The treatment in
the portable Gamow bag hyperbaric chamber lasted two hours, with a bag pressure of 103 mm
Hg (0.136 kg/cm2 or 2 psig) using ambient air, without the addition of oxygen. With this pressure
increase, the hyperbaric chamber lowered the patient’s effective ambient altitude from 6,050 to
4,400 m. The treatment was successful and the pulmonary oedema disappeared. Outside the
hyperbaric chamber, the patient recovered fully when he reached the altitude of 2,000 m. Portable
hyperbaric chamber is recommended for the treatment of severe cases of acute mountain sickness,
as well as for risky descent to lower altitudes.
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About 40 million people all over the world live
at altitudes over 2,500 m, and probably even more
people visit mountain areas every year, including
the top of the world, the 8,848 m high Mount
Everest (1). Many of these visitors will suffer from
some manifestation of high-altitude illness, that
is, mountain sickness. Beginning at altitudes of
2,000 to 3,000 m, some people suffer headache,
exhaustion, anxiety, dyspnoea and insomnia (2,
3). According to Dickinson and co-workers (4),
about 53% of visitors to an altitude over 5,000 m
such as Andes or Himalayas will experience a
certain degree of acute mountain sickness. A
minority or 4.3% will develop life-threatening
illness.
The principal cause of mountain sickness is
the decrease in partial pressure of oxygen at high
altitudes. Pathophysiologically speaking,
impaired production of energy leads to
intracellular and extracellular swelling. There are
three main manifestations of mountain sickness;
acute mountain sickness (AMS) with general
symptoms (mild headache, nausea, fatigue,
dyspnoea, and sleep disturbance), high-altitude
pulmonary oedema (HAPE) with predominantly
pulmonary symptoms (irritable and productive
cough, often bloody sputum, cyanosis,
tachycardia, increasing dyspnoea, and later
coma), and high-altitude cerebral oedema
(HACE) with predominantly cerebral symptoms
(severe headache, ataxia, mental confusion,
hallucination, and later coma). These
manifestations of mountain sickness are not
separate entities, but a continuum which is
dominated by one of them. For more details, we
recommend other sources (5, 6, 7).
Usually the prevention of mountain sickness
through long-term oxygen inhalation is notPartly presented at the 1st Croatian Congress on Maritime, Underwater
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4feasible for technical reasons. In ordinary high-
altitude climbing the only practical method to
prevent AMS is gradual acclimatisation. However,
this method has its limits. Until now AMS has best
been treated by a rapid descent into a valley or
by a decrease in altitude of at least 300 m.
However, climbing in the Himalayas, particularly
in Tibet, entails specific problems, as it is
necessary to walk some 20 km or more to achieve
the 300-metre decrease in altitude. In a case of
HACE, this is usually impossible. Helicopter
evacuation at altitudes over 6,000 m is not
feasible, as the air is too thin to provide adequate
lift (5).
In 1988, the American inventor Igor Gamow,
constructed a lightweight, portable low-volume
hyperbaric chamber made of PVC which has been
named the “Gamow bag” (Chinook Medical Gear
Inc, Eagle, CO-USA). The chamber is ideal for
the treatment of severe AMS manifestations in
high-altitude camps and expedition base camps.
Together with a transport bag and an air pump,
the Gamow bag weighs 6.76 kg. When inflated,
its volume is 0.476 m3. The maximal bag pressure
of 103 mm Hg (2 psig) is achieved with a foot
powered air pump or an electric pump. Ventilation
is accomplished with 10 to 20 pumping cycles
per minute (3).
Our experience
The expedition “Everest 97”, organized by the
Croatian Mountain Association, spent 38 days on
the Tibetan side of Mount Everest at altitudes over
5,200 m, of which 30 days were spent at altitudes
over 6,500 m in severe weather conditions (6).
At altitudes over 8,000 m, climbers had to breathe
oxygen-poor air and suffer continuous strong
winds bringing temperatures from -15 ˚C to -60
˚C every day. No wonder that members of the
expedition had numerous medical problems, of
whom 10 suffered from AMS. The expedition was
equipped with a portable hyperbaric chamber, the
so called Gamow bag, owned by the Baromedical
Polyclinic OXY from Pula, Croatia. The chamber
was provided specifically for that expedition, and
by good fortune, it was needed for the treatment
of one patient only. The other nine patients with
moderate AMS were treated by inhalation of
medical oxygen, diuretics and corticosteroids.
CASE REPORT
A 37-year-old member of the expedition
developed a life-threatening pulmonary oedema
during his ascent to an upper camp. On 3 May
1997, he arrived to Camp IV at 7,060 m on the
North Col of Mt Everest, showing symptoms of
HAPE after heavy physical exertion: dyspnoea,
shortness of breath, dry cough, and later the
appearance of foamy sputum. The expedition
physician was called over the mobile telephone,
and he soon climbed the glacier accompanied
by one climber. They brought the first aid kit and
a cylinder of medical oxygen, reserved solely for
medical treatment. They met the patient
descending slowly, assisted by another climber,
at the altitude of 6,650 m. The night was falling
and the air temperature dropped to -20 ˚C. The
patient was dyspnoeic and had rattled breathing,
rendering auscultation practically impossible. At
the meeting point he was given 100% oxygen via
a full-face mask, two 400 mg pills of pentoxifylline
orally (Trental, Belupo, Koprivnica, Croatia), and
16 mg of corticosteroids intravenously
(Dexamethason, Krka, Novo Mesto, Slovenia).
After a 15-minute rest, the evacuation was
resumed toward the advanced base camp at
6,450 m. The patient was immediately placed in
the Gamow bag and treated according to the
reference tables provided by Igor Gamow (3).
After two minutes of treatment, he was exposed
to an absolute pressure of 437 mm Hg (which
equals the pressure at the altitude of 4,400 m),
instead of the base camp air pressure of 333 mm
Hg (6,450 m).
After two hours of treatment, the symptoms
of pulmonary oedema were significantly relieved.
Full recovery took some time, with additional
medical care later including pentoxifylline pills t.
i. d. in the month that followed. Eighteen days
later, that experienced climber tried to climb the
top again despite the physician’s caution against
it, and his health deteriorated during that attempt.
The second exposure to the altitude of over 7,000
m caused severe circulatory problems in his legs
and probable peripheral nerve disturbances with
chilblains and painful muscle cramps, resistant
to therapy. His condition did not improve until he
returned to Katmandu (1,350 m), and he
completely recovered only after he returned home
a month later.
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In high mountains, climbers frequently
manifest different AMS symptoms. Dickinson and
co-workers in a paper describing seven fatalities
among trekkers in the Himalayas stress that in
all of them the cause of AMS was the rapid ascent
without acclimatisation (4). Ascents of over 5,000
m require acclimatization of at least seven days,
and the climbing of peaks of over 7,000 m is
recommended several weeks acclimatisation (5).
The diuretic acetazolamide is usual in the
treatment and prevention of HAPE and HACE.
Allegedly, this drug has been shown to decrease
the incidence of AMS (5, 7, 8). More recently,
corticosteroid therapy has been suggested, as has
oxygen breathing using a full-face mask which
has an exhalation valve with increased resistance
(8). However, no treatment equals rapid descent
to an altitude of at least 300-500 m below the
level at which the AMS symptoms appeared.
Medical literature on mountaineering has
recorded eight uses of the Gamow bag in which
seven patients were treated altogether. All of them
participated in expeditions to Mount Everest. The
highest point at which the chamber has been used
was on the Nepalese South Col at 8,004 m. Five
physicians have used the chamber and all
treatments were successful (3).
In the patient presented here the chamber was
used for first time in the history of Croatian
mountaineering medicine (6). Again the chamber
proved effective in the treatment of AMS.
The main motives for choosing the Gamow
bag to equip the 1997 Mount Everest expedition
for emergency were its price, simplicity of use,
and above all, its portability.
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6Saæetak
LIJE»ENJE VISINSKE BOLESTI NADTLAKOM
Alpinist obolio na Himalaji na nadmorskoj visini od 7.060 m od teπkog stupnja visinske bolesti s
izraæenim edemom pluÊa lijeËen je u laganoj prenosivoj hiperbariËnoj komori u najbliæem baznome
kampu na nadmorskoj visini od 6.050 m. LijeËenje u prenosivoj hiperbariËnoj komori nazvanoj
“Gamowova vreÊa” (engl. Gamow bag) trajalo je dva sata pod nadtlakom od 103 mm Hg. Za
tlaËenje hiperbariËne komore upotrijebljen je ambijentalni zrak bez dodavanja kisika. S tim
nadtlakom bolesniku se efektivna nadmorska visina od 6.050 praktiËno snizila na 4.400 m. Tijekom
tretmana simptomi i kliniËki znakovi edema pluÊa su nestali. Bolesnik se potpuno oporavio
silaskom na nadmorsku visinu od 2.000 m. Sugerira se tretman u prenosivoj hiperbariËnoj komori
za teæe sluËajeve akutne visinske bolesti i kao alternativa riziËnomu spuπtanju na niæu nadmorsku
visinu.
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